// App-Quantinova.ai

TPS1110 : First-in-human phase I/Ib multicenter, open-label dose escalation study to assess safety and tolerability of PMD-026 in patients with metastatic breast cancer with expansion in metastatic triple negative breast cancer.

Researchers

Presenter

  • Muralidhar Beeram

Principal Investigators

  • Judy Sing-Zan Wang

  • Lida A. Mina

  • Amita Patnaik

  • Mary Rose Pambid

  • Aarthi Jayanthan

  • My-my Huynh

  • Sandra Elaine Dunn

  • Gerrit Los

  • Andrew Dorr

Medical Centers

  • START, San Antonio, TX

  • Florida Cancer Specialists and Research Institute, Sarasota, FL

  • Banner MD Anderson Cancer Center, Mesa, AZ

  • Phoenix Molecular Designs, Vancouver, BC, Canada

  • Phoenix Molecular Designs, San Diego, CA

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Ribosomal Protein S6 Kinase A3

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Open Label

  • Single Arm

  • Multicenteric

  • Dose Escalation

  • Cohort

  • First-In-Human

Phase

  • NA

Study Id's

  • NCT04115306

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved